In March 2020, hydroxychloroquine (HCQ) and azithromycin were tested as potential treatments for in an open label non-randomized clinical trial [1]. Data were collected from 36 confirmed COVID-19 patients after receiving no treatment (n = 16) or 200 mg q8h of HCQ with (n = 6) or without (n = 14) azithromycin depending on clinical status. Collected data over six days included one HCQ concentration per patient; respiratory viral loads (PCR assay); azithromycin co-treatment; and clinical status among other variables.Using observed HCQ concentrations and basic pharmacokinetic equations, it was possible to calculate missing concentrations at all days for all patients ( Supplementary Fig. S1). Daily viral load, presented as PCR threshold cycle (CT), was converted into a dichotomous variable (positive-PCR or negative-PCR). A logistic regression evaluated whether HCQ concentrations, azithromycin co-treatment (yes/no), clinical status (asymptomatic, upper or lower respiratory tract infection [URTI or LRTI]), time (day 0-6), and other covariates (age, sex) were associated with response (positive-PCR outcome).Model evaluation and selection was performed based on statistical significance (p-value B 0.05) and diagnostic plots ( Supplementary Figs. S2, S3). The final model contained HCQ log-concentrations (ng/ml), azithromycin cotreatment, clinical status, and day as statistically significant covariates ( Figs. 1 and S4).Results showed that the odds of positive-PCR decrease by 53% for each unit increase in HCQ log-concentration. Similarly, the odds decrease by 61%, and by 12% for each day increase, and for azithromycin co-treatment, respectively. Whereas the odds of positive-PCR increase by 99.4 folds and 212 folds for having URTI and LRTI versus being asymptomatic subject.Using the model, minimum HCQ concentrations to achieve [ 50% probability of negative-PCR on day 3 were calculated, with or without azithromycin, for the clinical statuses. A minimum HCQ concentration (ng/ml) of 8103 (without azithromycin) and 282 (with azithromycin) are needed in subjects with LRTI. A minimum HCQ concentration (ng/ml) of 2441 (without azithromycin) and 83.9 (with azithromycin) are needed in subjects with URTI. Asymptomatic patients require minimal HCQ concentrations (\ 2 ng/ml) regardless of azithromycin co-treatment.Next, HCQ population PK model [2] was used to simulate dosing regimens needed to achieve targeted HCQ concentrations. Simulations showed that when HCQ is coadministered with azithromycin, a loading dose is critical in rapid achievement of targeted concentrations. The suggested dosing regimen for HCQ (with azithromycin), is 600 mg at 0 and 400 at 8 h followed by 200 mg q8h ( Supplementary Fig. S5). When HCQ is administered without azithromycin, no safe and suitable HCQ dose can achieve targeted concentrations in LRTI and URTI patients ( Supplementary Fig. S6).The analysis confirms that co-treatment of COVID-19 with HCQ and azithromycin increases the probability of negative-PCR in patients. It also shows that clinical status af...